FDA deploys internal generative-AI tooling to speed scientific reviews (“Elsa”) + agency-wide rollout
FDA launched / expanded a generative AI tool to accelerate scientific reviews and related tasks; Reuters describes intended uses and rollout context.
FDA also issued its own announcement about completing an AI-assisted review pilot and scaling AI internally.
Why it matters for pharma: This affects how fast and how consistently regulators can process submissions, identify issues, and target inspections. Even if Elsa is “internal,” it changes the regulatory interface pharma works with.
Reuters coverage: https://www.reuters. … -reviews-2025-06-02/
FDA press announcement: https://www.fda.gov/ … ssive-agency-wide-ai